Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent

Table 2

Univariate and multivariate analysis of survival in patients with colorectal cancer, treated with melphalan or mitomycin-C as a HIPEC agent.

		Univariate		Multivariate
Characteristics	n	Median survival months (95%CI)	p-value	HR; (95%CI)	p-value
Agent			0.54		0.24
Melphalan	18	36 (17-55)		1.66 (0.7-3.95)
Mitomycin-C	27	28 (8-47)
Age			0.42		0.24
≤53	31	37 (23-51)
>53	14	30 (11-49)		1.62 (0.72-3.64)
CC score			0.026		0.69
CC-0	37	36 (24-49)
CC-1	8	24 (3-47)		1.25 (0.43-3.64)
PCI			<0.001		<0.001
≤20	24	46 (29-64)
>20	20	18 (12-24)		7.5 (2.76-20.4)
LN status			0.49		1
no LN metastases	22	37 (35-39)
LN metastases	19	27 (18-35)		1 (0.44-2.27)

HR: hazard ratio; CI: confidence interval; PCI: peritoneal carcinomatosis index; LN: lymph nodes; used as reference; patients with >1 CRS/HIPEC were excluded from the analysis.